• Emergent BioSolutions received a delivery order modification worth up to $22.3 million to supply BioThrax anthrax vaccine to the U.S. Department of War.
• Initial deliveries worth approximately $7.4 million begin this year; remaining deliveries are expected in 2027.
• The vaccine will support anthrax pre-exposure prevention across all branches of the U.S. military.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Emergent BioSolutions Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611041605BIZWIRE_USPR_____20261104_BW083043) on November 04, 2026, and is solely responsible for the information contained therein.